Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
- Monday, March 1, 2021, 7:16
- PR Newswire
- Add a comment
CARLSBAD, Calif., March 1, 2021 /PRNewswire/ — Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers whose work advances the understanding of transthyretin amyloidosis (ATTR), facilitates…
About the Author
admin has written 20652 stories on this site.